[Perspectives of the novel drug divaza in the treatment of chronic cerebral ischemia].

The present paper reviews preclinical research of divaza, the combination of release-active antibodies to brain-specific 5100 protein and release-active antibodies to endothelial NO-synthase. Preclinical studies have revealed that the specific pharmacological activity of the compounds is retained in the combination, and the components mutually potentiate each other's effects. The previous research have demonstrated high efficacy of divaza in the experimental models of cerebral ischemia and neurodegenerative diseases.

[Immunotropic properties of anaferon and anaferon pediatric].

Anaferon and pediatric anaferon based on release-active antibodies to interferon-gamma (R-A antibodies to INF-gamma) proved to be efficient in the treatment of many viral infections. Immunomodulating (immunotropic) properties of the drugs were revealed in the preclinical studies at many Russian and foreign research medical institutions and are reviewed herein. Anaferon and pediatric anaferon stimulated the humoral and cellular immune responses and increased the neutrophil and macrophage activity.

[Effect of kardostin on the generative function of female rats].

The effects of kardostin on the ovulatory cycle, conception, and sexual behavior of female rats have been experimentally studied. It is established that a two-week therapy with kardostin at a dose of 5 and 15 mg/kg changed phases of the estrous cycle (with the estrus phase being most prevalent) and led to ambiguous changes in the sexual behavior of female rats (a dose of 5 mg/kg increased sexual behavior, while a dose of 15 mg/kg inhibited it), activated fertility, and improved the quality of conception.

[Use of ultralow doses of antibodies to gamma-interferon in the treatment and prophylaxis of viral infections].

Viral infections are at present the leading cause of morbidity in the world. The clinical trials of gamma-anaferon (pediatric formulation) in the treatment and prophylaxis of a great number of viral infections (more than 20 nosological forms) due to the RNA- and DNA-containing viruses demonstrated its efficacy and safety. Gamma-anaferon is an immunomodulator with antiviral activity containing ultralow doses of antibodies to interferon.